Mechanisms of cardiovascular damage in obstructive sleep apnea;Mecanismos de daño cardiovascular en apnea obstructiva del sueño

Revista de Investigacion Clinica

Volumn 60, Issue 6, 2008, Pages 502-516

  Torre Bouscoulet, Luis ^a   Castorena Maldonado, Armando ^a   Sada Ovalle, Isabel ^a   Meza Vargas, María Sonia ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Arterial hypertension; Cardiovascular risk; Intermittent hypoxemia; Oxidative stress; Sleep apnea

Indexed keywords

CD15 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; GELATINASE B; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMORECEPTOR REFLEX; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXEMIA; INFLAMMATION; INSULIN RESISTANCE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRESSORECEPTOR REFLEX; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REOXYGENATION; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; TREATMENT RESPONSE;

ANIMALS; ANOXIA; ATHEROSCLEROSIS; BAROREFLEX; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CONTINUOUS POSITIVE AIRWAY PRESSURE; CYTOKINES; DYSLIPIDEMIAS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; REFLEX, ABNORMAL; RENIN-ANGIOTENSIN SYSTEM; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM;

EID: 63649111107     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-5.
2. Torre-Bouscoulet L, Chávez E, Meza MS, Vézquez JC, Franco F, et al. Snoring and Sleep-related Symptoms in Three Latin-American Cities. Proc Am Thorac Soc 2005; 2: A767.
3. Caples SM, Garcia-Touchard A, Somers VK. Sleep-disordered breathing and cardiovascular risk. Sleep 2007; 30: 291-303.
4. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84.
5. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J 2006; 28: 596-602.
6. Orea-Tejeda A, Valencia-Flores M, Castillo-Martinez L, et al. Abnormal SPECT myocardial perfusion imaging during periods of obstructive sleep apnea in morbid obese patients without known heart disease. Rev Invest Clin 2003; 55:18-25.
7. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034-41.
8. Atwood CW Jr., McCrory D, Garcia JG, et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 72S-77S.
9. Valencia-Flores M, Rebollar V, Santiago V, et al. Prevalence of pulmonary hypertension and its association with respiratory disturbances in obese patients living at moderately high altitude. Int J Obes Relat Metab Disord 2004; 28: 1174-80.
10. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173: 910-16.
11. Valencia-Flores M, Orea A, Castano VA, et al. Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. Obes Res 2000; 8: 262-9.
12. Bradley TD, Floras JS. Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation 2003; 107: 1671-8.
13. Gami AS, Howard DE, Olson EJ, et al. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005; 352: 1206-14.
14. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625-30.
15. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290-7.
16. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoeahypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.
17. Kribbs NB, Pack AI, Kline LR, et al. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 147: 887-95,
18. Kushida CA, Littner MR, Hirshkowitz M, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 2006; 29: 375-80.
19. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001; 164: 2147-65.
20. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14.
21. Fletcher EC, Lesske J, Qian W, et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555-61.
22. Brooks D, Horner RL, Kimoff RJ, et al. Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Am J Respir Crit Care Med 1997; 155: 1609-17.
23. Farre R, Nacher M, Serrano-Mollar A, et al. Rat model of chronic recurrent airway obstructions to study the sleep apnea syndrome. Sleep 2007; 30: 930-3.
24. Leuenberger UA, Brubaker D, Quraishi S, et al. Effects of intermittent hypoxia on sympathetic activity and blood pressure in humans. Auton Neurosci 2005; 121: 87-93.
25. Narkiewicz K, van de Borne PJ, Pesek CA, et al. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183-9.
26. Somers VK, Mark AL, Zavala DC, et al. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989; 67: 2101-6.
27. Smith ML, Pacchia CF. Sleep apnoea and hypertension: role of chemoreflexes in humans. Exp Physiol 2007; 92: 45-50.
28. Tamisier R, Nieto L, Anand A, et al. Sustained muscle sympathetic activity after hypercapnic but not hypocapnic hypoxia in normal humans. Respir Physiol Neurobiol 2004: 141: 145-55.
29. Somers VK, Mark AL, Zavala DC, et al. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989; 67: 2095-100.
30. Narkiewicz K, van de Borne PJ, Montano N, et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998; 97: 943-5.
31. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003; 26: 15-9.
32. Cutler MJ, Swift NM, Keller DM, et al. Periods of intermittent hypoxic apnea can alter chemoreflex control of sympathetic nerve activity in humans. Am J Physiol Heart Circ Physiol 2004; 287: H2054-H2060.
33. Garcia-Rio F, Racionero MA, Pino JM, et al. Sleep apnea and hypertension. Chest 2000; 117: 1417-25.
34. Carlson JT, Hedner J, Elam M, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763-68.
35. Fletcher EC, Lesske J, Culman J, et al. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992; 20: 612-19.
36. Lesske J, Fletcher EC, Bao G, et al. Hypertension caused by chronic intermittent hypoxia - influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997; 15: 1593-603.
37. Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 1997; 15: 1613-19.
38. Imadojemu VA, Mawji Z, Kunselman A, et al. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest 2007; 131: 1406-13.
39. Peng YJ, Prabhakar NR. Effect of two paradigms of chronic intermittent hypoxia on carotid body sensory activity. J Appl Physiol 2004; 96: 1236-42; discussion 1196.
40. Prabhakar NR, Dick TE, Nanduri J, et al. Systemic, cellular and molecular analysis of chemoreflex-mediated sympatho-excitation by chronic intermittent bypoxia. Exp Physiol 2007; 92: 39-44.
41. Suzuki YJ, Jain V, Park AM, et al. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med 2006; 40: 1683-92.
42. Suzuki YJ, Ford GD. Redox regulation of signal transduction in cardiac and smooth muscle. J Mol Cell Cardiol 1999; 31: 345-53.
43. Peng YJ, Overholt JL, Kline D, et al. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. Proc Natl Acad Sci U S A 2003; 100: 10073-8.
44. Kumar GK, Rai V, Sharma SD, et al. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress. J Physiol 2006; 575: 229-39.
45. Christou K, Markoulis N, Moulas AN, et al. Reactive oxygen metabolites (ROMs) as an index of oxidative stress in obstructive sleep apnea patients. Sleep Breath 2003; 7: 105-10.
46. Yamauchi M, Nakano H, Maekawa J, et al. Oxidative stress in obstructive sleep apnea. Chest 2005; 127: 1674-9.
47. Christou K, Moulas AN, Pastaka C, et al. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med 2003; 4: 225-8.
48. Barcelo A, Miralles C, Barbe F, et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16: 644-7.
49. Carpagnano GE, Kharitonov SA, Resta O, et al. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-92.
50. Yuan G, Nanduri J, Bhasker CR, et al. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280: 4321-28
51. Peng YJ, Yuan G, Ramakrishnan D, et al. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006; 577: 705-16.
52. Chen J, He L, Dinger B, et al. Role of endothelin and endothelin A-type receptor in adaptation of the carotid body to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1314-L1323
53. Weiss JW, Liu MD, Huang J. Physiological basis for a causal relationship of obstructive sleep apnoea to hypertension. Exp Physiol 2007; 92: 21-6.
54. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol 2002; 92: 627-33.
55. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003; 10: 184-96.
56. Moller DS, Lind P, Strunge B, et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003; 16: 274-80.
57. Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol 2002; 283: R815-R826.
58. Lai CJ, Yang CC, Hsu YY, et al. Enhanced sympathetic outflow and decreased baroreflex sensitivity are associated with intermittent hypoxia-induced systemic hypertension in conscious rats. J Appl Physiol 2006; 100: 1974-82.
59. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008; 177: 227-35.
60. Ryan S, Ward S, Heneghan C, et al. Predictors of decreased spontaneous baroreflex sensitivity in obstructive sleep apnea syndrome. Chest 2007; 131: 1100-07.
61. Grassi G, Seravalle G, Colombo M, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-42.
62. Bonsignore MR, Parati G, Insalaco G, et al. Continuous positive airway pressure treatment improves baroreflex control of heart rate during sleep in severe obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2002; 166: 279-86.
63. Lavie L, Hefetz A, Luboshitzky R, et al. Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. J Mol Neurosci 2003; 21: 57-63.
64. Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000; 55: 1046-51.
65. Ip MS, Larn B, Chan LY, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162: 2166-71.
66. Foster GE, Poulin MJ, Hanly PJ. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 2007; 92: 51-65.
67. Phillips SA, Olson EB, Morgan BJ, et al. Chronic intermittent hypoxia impairs endothelium-dependent dilation in rat cerebral and skeletal muscle resistance arteries. Am J Physiol Heart Circ Physiol 2004; 286: H388-H393.
68. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004; 36: 707-17.
69. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003; 93: 1034-46.
70. Suzuki YJ, Ford GD. Superoxide stimulates IP3-induced Ca2+ release from vascular smooth muscle sarcoplasmic reticulum. Am J Physiol 1992; 262:H114-H116
71. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-9.
72. El Solh AA, Akinnusi ME, Baddoura FH, et al. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007; 175: 1186-91.
73. Lattimore JL, Wilcox I, Skilton M, et al. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 2006; 61: 491-5.
74. El Solh AA, Saliba R, Bosinski T, et al. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J 2006; 27: 997-1002.
75. Grebe M, Eisele HJ, Weissmann N, et al. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 2006; 173: 897-901.
76. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
77. Chin K, Nakamura T, Shimizu K, et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000; 109: 562-7.
78. Ursavas A, Karadag M, Rodoplu E, et al. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 2007; 74: 525-32.
79. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999; 87: 10-14.
80. Costanzo A, Moretti F, Burgio VL, et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195: 402-10.
81. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-82.
82. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-9.
83. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000; 162: 566-70.
84. Cadroy Y, Dupouy D, Boneu B, et al. Polymorphonuclear leukocytes modulate tissue factor production by mononuclear cells: role of reactive oxygen species. J Immunol 2000; 164: 3822-8.
85. Htoo AK, Greenberg H, Tongia S, et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006; 10: 43-50.
86. Maianski NA, Maianski AN, Kuijpers TW, et al. Apoptosis of neutrophils. Acta Haematol 2004; 111: 56-66.
87. Chen L, Zhang J, Gan TX, et al. Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia. J Appl Physiol 2008; 104: 218-23.
88. Dyugovskaya L, Polyakov A, Lavie P, et al, Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 2008; 177: 544-54.
89. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613-18.
90. Suzuki T, Nakano H, Maekawa J, et al. Obstructive sleep apnea and carotid-artery intima-media thickness. Sleep 2004; 27: 129-33.
91. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-34.
92. Drager LF, Bortolotto LA, Figueiredo AC, et al. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176: 706-12.
93. Li J, Savransky V, Nanayakkara A, et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-63.
94. McArdle N, Hillman D, Beilin L, et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007; 175: 190-5.
95. Robinson GV, Pepperell JC, Segal HC, et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004; 59: 777-82.
96. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-8.
97. Carrell TW, Burnand KG, Wells GM, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002; 105: 477-82.
98. Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 2041-8.
99. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
100. Tazaki T, Minoguchi K, Yokoe T, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 170: 1354-9.
101. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-7.
102. Nanduri J, Nanduri RP. Cellular mechanisms associated with intermittent hypoxia. Essays Biochem 2007; 43: 91-104.
103. Greenberg H, Ye X, Wilson D, et al. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006; 343: 591-6.
104. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126:1473-1479
105. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-83
106. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-10.
107. Tam CS, Wong M, Tam K, et al. The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep 2007; 30: 723-7.
108. Ghosh S, May MJ, Kopp EB. NF-kappa B and Re1 proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
109. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992; 17: 221-37.
110. Semenza GL. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004; 96: 1173-7; discussion 1170-2.
111. Lavie L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
112. Yamauchi M, Tamaki S, Tomoda K, et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006; 10: 189-93.
113. Lavie L, Kraiczi H, Hefetz A, et al. Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment. Am J Respir Crit Care Med 2002; 165: 1624-8.
114. Schulz R, Hummel C, Heinemann S, et al. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002; 165: 67-70.
115. Winnicki M, Shamsuzzaman A, Lanfranchi P, et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004; 17: 783-6.
116. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174: 824-30.
117. Vgontzas AN, Zoumakis E, Lin HM, et al. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 2004; 89: 4409-13.
118. Joyeux-Faure M, Stanke-Labesque F, Lefebvre B, et al. Chronic intermittent hypoxia increases infarction in the isolated rat heart. J Appl Physiol 2005; 98: 1691-6.
119. Chen L, Zhang J, Gan TX, et al. Left Ventricular Dysfunction and Associated Cellular Injury in Rats exposed to Chronic Intermittent Hypoxia. J Appl Physiol 2008; 104:(1) 218-223.
120. Lee SD, Kuo WW, Lin JA, et al. Effects of long-term intermittent hypoxia on mitochondrial and Fas death receptor dependent apoptotic pathways in rat hearts. Int J Cardiol 2007; 116: 348-56.
121. Chen L, Einbinder E, Zhang Q, et al. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005; 172: 915-20.
122. Romero-Corral A, Somers VK, Pellikka PA, et al. Decreased right and left ventricular myocardial performance in obstructive sleep apnea. Chest 2007; 132: 1863-70.
123. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110: 364-7.
124. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-71.
125. Stradling JR, Barbour C, Glennon J, et al. Which aspects of breathing during sleep influence the overnight fall of blood pressure in a community population? Thorax 2000; 55: 393-8.
126. Iber C, Ancoli-Israel S, Chesson AL, Jr., et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, 1st. Ed. Westchester, Illinois: American Academy of Sleep Medicine; 2007.
127. White DP. Sleep apnea. Proc Am Thorac Soc 2006; 3: 124-8.
128. Horner RL, Brooks D, Kozar LF, et al. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol 1995; 79: 151-62.
129. Noda A, Yasuma F, Okada T, et al. Influence of movement arousal on circadian rhythm of blood pressure in obstructive sleep apnea syndrome. J Hypertens 2000; 18: 539-44.
130. Lofaso F, Coste A, Gilain L, et al. Sleep fragmentation as a risk factor for hypertension in middle-aged nonapneic snorers. Chest 1996; 109: 896-900.
131. Sulit L, Storfer-Isser A, Kirchner HL, et al. Differences in polysomnography predictors for hypertension and impaired glucose tolerance. Sleep 2006; 29: 777-83.
132. Punjabi NM, Shahar E, Redline S, et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004; 160: 521-30.
133. Oltmanns KM, Gehring H, Rudolf S, et al. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med 2004; 169: 1231-7.
134. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-7.
135. Norman D, Loredo JS, Nelesen RA, et al. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 2006; 47: 840-5.
136. Perry JC, D'Almeida V, Souza FG, et al. Consequences of subchronic and chronic exposure to intermittent hypoxia and sleep deprivation on cardiovascular risk factors in rats. Respir Physiol Neurobiol 2007; 156: 250-8.
137. Hui DS, Ko FW, Fok JP, et al. The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 2004; 125: 1768-75.
138. Gottlieb DJ, Redline S, Nieto FJ, et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep 2006; 29: 1009-14.
139. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4.
140. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of Creactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111: 1978-84.
141. von Kanel R, Loredo JS, Ancoli-Israel S, et al. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 2007; 131: 733-9.
142. Jeppesen J, Hansen TW, Rasmussen S, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49: 2112-19.
143. Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-6.
144. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156-62.
145. Polotsky VY, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552: 253-64.
146. Seufert J, Kieffer TJ, Habener JF. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci USA 1999; 96: 674-9.
147. Barzilai N, Wang J, Massilon D, et al. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997; 100: 3105-10.
148. Ambrosini G, Nath AK, Sierra-Honigmann MR, et al. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 2002; 277: 34601-09.
149. Ceddia RB, Koistinen HA, Zierath JR, et al. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163-76.
150. Larsen JJ, Hansen JM, Olsen NV, et al. The effect of altitude hypoxia on glucose homeostasis in men. J Physiol 1997; 504 (Pt. 1): 241-9.
151. Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab 2006; 8: 250-60.
152. Narkiewicz K, van de Borne PJ, Cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-6.
153. Allahdadi KJ, Walker BR, Kanagy NL. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension 2005; 45: 705-9.
154. Allahdadi KJ, Duling LC, Walker BR, et al. Eucapnic intermittent hypoxia augments endothelin-1 vasoconstriction in rats: role of PKCdelta. Am J Physiol Heart Circ Physiol 2008; 294: H920-H927.
155. Grimpen F, Kanne P, Schulz E, et al. Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000; 15; 320-5.
156. Jordan W, Reinbacher A, Cohrs S, et al. Obstructive sleep apnea: Plasma endothelin-1 precursor but not endothelin-1 levels are elevated and decline with nasal continuous positive airway pressure. Peptides 2005; 26: 1654-60.
157. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004; 111: 683-9.
158. Svatikova A, Wolk R, Magera MJ, et al. Plasma homocysteine in obstructive sleep apnoea. Eur Heart J 2004; 25: 1325-9.
159. Nakao K, Ohgushi M, Yoshimura M, et al. Hyperventilation as a specific test for diagnosis of coronary artery spasm. Am J Cardiol 1997; 80: 545-9.
160. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999; 341: 949-54.
161. White DP. Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 2005; 172: 1363-70.
162. von Kanel R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003; 124: 1956-67.
163. Chin K, Ohi M, Kita H, et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996; 153: 1972-6.
164. von Kanel R, Le DT, Nelesen RA, et al. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 2001; 19: 1445-51.
165. Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002; 69: 229-34.
166. Veasey SC. Obstructive sleep apnea: re-evaluating our index of severity. Sleep Med 2006; 7: 5-6.
167. Lopez-Jimenez F, Somers VK. Stress measures linking sleep apnea, hypertension and diabetes - AHI vs arousals vs hypoxemia. Sleep 2006; 29: 743-44.
168. Barbe F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness, a randomized, controlled trial. Ann Intern Med 2001; 134: 1015-23.
169. George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001; 56: 508-12.
170. Torre-Bouscoulet L, Castorena-Maldonado A, Meza-Vargas MS. Otras consecuencias de los trastornos del dormir. A propósito de los accidentes vehiculares. Rev Inst Nal Enf Resp Mex 2005; 18: 162-9.
171. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12.
172. Prabhakar NR, Kumar GK, Nanduri J, et al. ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007; 9: 1397-403.
173. Baldwin CM, Bootzin RR, Schwenke DC, et al. Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. Sleep Med Rev 2005; 9: 459-76.
174. Mills PJ, Kennedy BP, Loredo JS, et al. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 2006; 100: 343-8.
175. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96:1897-904.